NITI Aayog charts 2047 roadmap to expand India's Bioeconomy to $2.6 trillion
NITI Aayog released a report charting a roadmap to expand India's bioeconomy to USD 2.6 trillion by 2047, India's centenary of independence
The roadmap sets an interim target of USD 691 billion by 2035, up from an estimated USD 195.3 billion in 2025
The report calls for mission-mode execution, proposing six National BioMissions covering gene and cell therapies, climate-resilient agriculture, synthetic biology, disease surveillance, marine biotechnology, and next-generation biopharmaceuticals
It recommends a Rs 50,000-crore BioEconomy Growth Fund for 2026-2035 to bridge the gap between laboratory research and commercial-scale manufacturing, along with PLI-style incentives, faster regulatory approvals, and stronger intellectual property protection
The roadmap frames the goal as positioning India among the world's top three biotechnology powers, with the potential to create over 30 million high-value jobs
Bioeconomy and India's BioE3 Policy (2024)
A bioeconomy refers to the segment of economic activity that uses biological resources, processes, and technologies — biotechnology, biomanufacturing, agriculture, pharmaceuticals, and bio-based industrial products — as core inputs. India's Union Cabinet approved the BioE3 Policy (Biotechnology for Economy, Environment and Employment) on August 24, 2024, to be implemented by the Department of Biotechnology (DBT), providing the policy foundation the NITI Aayog roadmap now builds a longer-term 2047 target on top of.
Key Details
- BioE3 Policy's strategic/thematic sectors include high-value bio-based chemicals, biopolymers and enzymes; smart proteins and functional foods; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and marine and space research
- The policy's stated mechanisms include establishing Biomanufacturing and Bio-AI Hubs and Biofoundries to accelerate technology development and commercialisation
- The Department of Biotechnology (DBT) was established in 1986 under the Ministry of Science and Technology and is the nodal body for India's biotechnology policy, including implementation of BioE3
The NITI Aayog 2047 roadmap extends the sectoral priorities already laid out in the 2024 BioE3 Policy into a long-horizon, quantified national target, with the proposed BioMissions mapping closely onto BioE3's thematic sectors (e.g., gene/cell therapies and precision biotherapeutics; climate-resilient agriculture appears in both).
Production-Linked Incentive (PLI) Framework Applied to Biotechnology
Production-Linked Incentive (PLI) schemes are a Government of India instrument that offers financial incentives to companies based on incremental production/sales, rather than upfront capital subsidies, aimed at boosting domestic manufacturing and reducing import dependence in strategic sectors.
Key Details
- PLI schemes were first introduced in 2020 for sectors including mobile manufacturing and later extended to pharmaceuticals, medical devices, and bulk drugs (Active Pharmaceutical Ingredients) — sectors adjacent to biomanufacturing
- The NITI Aayog roadmap recommends "PLI-style incentives" specifically for biomanufacturing, signalling an extension of the PLI logic (incentivise output, not just investment) into the bioeconomy space, which is not yet covered by a dedicated biotech PLI scheme
- This is paired with the proposed Rs 50,000-crore BioEconomy Growth Fund (2026-2035), targeted at de-risking the transition from lab-scale research to commercial manufacturing — a stage often called the "valley of death" in biotech commercialisation
By proposing PLI-style incentives alongside a dedicated growth fund, the roadmap seeks to replicate a policy tool that has shown results in electronics and pharma manufacturing, applied now to biomanufacturing scale-up.
Biotechnology Regulatory and Institutional Ecosystem
India's biotechnology sector operates under a multi-institutional regulatory and promotional ecosystem. The Department of Biotechnology (DBT) sets policy, while the Biotechnology Industry Research Assistance Council (BIRAC), a not-for-profit Public Sector Undertaking under DBT (established 2012), funds and mentors biotech startups and early-stage innovation, bridging the gap between academic research and industry.
Key Details
- BIRAC's mandate includes seed funding, industry-academia partnerships, and technology transfer support for biotech entrepreneurs — an institutional structure central to translating the roadmap's "mission-mode execution" ambition into implementation
- The National Biopharma Mission (2017), an earlier DBT initiative implemented via BIRAC, focused on accelerating biopharmaceutical development, an antecedent to the current roadmap's "next-generation biopharmaceuticals" mission theme
- India's bioeconomy currently contributes an estimated 4.8% to national GDP, reflecting a sixteen-fold expansion from USD 10 billion (2014) to USD 195.3 billion (2025)
The scale of ambition in the 2047 roadmap (targeting a top-three global biotech power position) depends on strengthening this existing DBT-BIRAC institutional chain, alongside the new funding and regulatory measures proposed.
- 2047 target: USD 2.6 trillion bioeconomy (India's centenary of independence)
- 2035 interim target: USD 691 billion
- 2025 estimated bioeconomy size: USD 195.3 billion (up from USD 10 billion in 2014 — a sixteen-fold increase)
- Current contribution to GDP: approximately 4.8%
- Proposed BioEconomy Growth Fund: Rs 50,000 crore, for the period 2026-2035
- Six proposed National BioMissions: gene and cell therapies, climate-resilient agriculture, synthetic biology, disease surveillance, marine biotechnology, next-generation biopharmaceuticals
- Projected job creation: over 30 million high-value jobs
- BioE3 Policy approved by Union Cabinet: August 24, 2024
- Nodal ministry/department: Department of Biotechnology (DBT), established 1986
- Ambition: India among the world's top three biotechnology powers